GSK1358820

DRUG6 trials

Sponsors

GlaxoSmithKline

Conditions

Cerebrovascular AccidentHyperhidrosisPost-Stroke SpasticityStrabismusUrinary Bladder, Overactive

Phase 3

Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity

CompletedNCT00460564

GlaxoSmithKlineCerebrovascular Accident, Post-Stroke Spasticity

Start: 2007-05-31End: 2008-12-31Updated: 2017-05-30

Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity

CompletedNCT00460655

GlaxoSmithKlineCerebrovascular Accident, Post-Stroke Spasticity

Start: 2007-05-31End: 2008-12-31Updated: 2010-09-08

GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis

CompletedNCT01128738

GlaxoSmithKlineHyperhidrosis

Start: 2010-04-30End: 2011-08-31Updated: 2015-06-08

Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus

CompletedNCT01584843

GlaxoSmithKlineStrabismus

Start: 2012-05-31End: 2014-06-30Updated: 2015-07-24

Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder

CompletedNCT02820844

GlaxoSmithKlineUrinary Bladder, Overactive

Start: 2016-08-10End: 2018-11-12Updated: 2020-11-27

Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity

CompletedNCT02849418

GlaxoSmithKlineUrinary Bladder, Overactive

Start: 2016-10-11End: 2018-12-20Updated: 2021-07-14

Related Papers

Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial

International Urology and Nephrology2021-07-227 citations

Botulinum toxin type A in post-stroke upper limb spasticity.

2010-08-0172 citations